PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.
Antigens, Neoplasm
/ immunology
Apyrase
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Female
Gene Expression
Head and Neck Neoplasms
/ genetics
Humans
Immune Tolerance
/ genetics
Immunity, Cellular
/ genetics
In Vitro Techniques
Lymphocyte Activation
/ genetics
Lymphocyte Cooperation
/ genetics
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Ovarian Neoplasms
/ genetics
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
RNA, Messenger
/ genetics
T-Lymphocytes, Helper-Inducer
/ immunology
Tumor Escape
/ genetics
Uterine Cervical Neoplasms
/ genetics
Cancer immunotherapy
Immunology
T cells
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
25 01 2021
25 01 2021
Historique:
received:
24
07
2020
accepted:
09
12
2020
pubmed:
18
12
2020
medline:
5
6
2021
entrez:
17
12
2020
Statut:
epublish
Résumé
Tumor antigen-specific CD4 T cells accumulate at tumor sites, evoking their involvement in antitumor effector functions in situ. Contrary to CD8 cytotoxic T lymphocyte exhaustion, that of CD4 T cells remains poorly appreciated. Here, using phenotypic, transcriptomic, and functional approaches, we characterized CD4 T cell exhaustion in patients with head and neck, cervical, and ovarian cancer. We identified a CD4 tumor-infiltrating lymphocyte (TIL) population, defined by high PD-1 and CD39 expression, which contained high proportions of cytokine-producing cells, although the quantity of cytokines produced by these cells was low, evoking an exhausted state. Terminal exhaustion of CD4 TILs was instated regardless of TIM-3 expression, suggesting divergence with CD8 T cell exhaustion. scRNA-Seq and further phenotypic analyses uncovered similarities with the CD8 T cell exhaustion program. In particular, PD-1hiCD39+ CD4 TILs expressed the exhaustion transcription factor TOX and the chemokine CXCL13 and were tumor antigen specific. In vitro, PD-1 blockade enhanced CD4 TIL activation, as evidenced by increased CD154 expression and cytokine secretion, leading to improved dendritic cell maturation and consequently higher tumor-specific CD8 T cell proliferation. Our data identify exhausted CD4 TILs as players in responsiveness to immune checkpoint blockade.
Identifiants
pubmed: 33332284
pii: 142513
doi: 10.1172/jci.insight.142513
pmc: PMC7934837
doi:
pii:
Substances chimiques
Antigens, Neoplasm
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
RNA, Messenger
0
Apyrase
EC 3.6.1.5
ENTPD1 protein, human
EC 3.6.1.5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
Nat Methods. 2017 Sep;14(9):865-868
pubmed: 28759029
Cancer Res. 2012 Mar 1;72(5):1059-63
pubmed: 22253231
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Cancer Immunol Res. 2013 Nov;1(5):303-8
pubmed: 24777968
J Exp Med. 2017 Jun 5;214(6):1567-1580
pubmed: 28526759
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
Immunity. 2018 May 15;48(5):1029-1045.e5
pubmed: 29768164
J Clin Invest. 2004 Apr;113(8):1225-33
pubmed: 15085202
BMC Genomics. 2018 Jun 19;19(1):477
pubmed: 29914354
Nature. 2019 Jul;571(7764):270-274
pubmed: 31207604
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Nucleic Acids Res. 2019 Dec 2;47(21):e133
pubmed: 31294801
Nature. 2019 Jul;571(7764):265-269
pubmed: 31207605
Nat Biotechnol. 2019 May;37(5):547-554
pubmed: 30936559
Nat Immunol. 2013 Dec;14(12):1285-93
pubmed: 24162775
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
Cancer Immunol Res. 2020 Jul;8(7):869-882
pubmed: 32295784
Cancer Immunol Res. 2019 May;7(5):784-796
pubmed: 30872264
Nat Commun. 2018 Jul 13;9(1):2724
pubmed: 30006565
Cancer Res. 2018 Jul 1;78(13):3604-3618
pubmed: 29559470
Cell Rep. 2019 May 21;27(8):2411-2425.e9
pubmed: 31116985
Nat Commun. 2018 Sep 19;9(1):3762
pubmed: 30232328
J Immunol. 2015 Apr 1;194(7):3475-86
pubmed: 25725111
NAR Genom Bioinform. 2020 Apr 20;2(2):lqaa025
pubmed: 33575582
Cancer Immunol Res. 2020 Oct;8(10):1311-1321
pubmed: 32759363
Nature. 2019 Jul;571(7764):211-218
pubmed: 31207603
Cancer Immunol Res. 2014 Feb;2(2):91-8
pubmed: 24778273
Nature. 2019 Oct;574(7780):696-701
pubmed: 31645760
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998
pubmed: 28446615
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023